Mark Gorman
Director of Survivorship Policy,
National Coalition for Cancer Survivorship

NCCS’s mission is to advocate for quality cancer care. NCCS believes in evidence-based advocacy for systemic changes at the federal level in how the nation researches, regulates, finances, and delivers quality cancer care. A key focus of NCCS's cancer survivorship is advocacy to improve the patient experience of those living with cancer, both during and after the acute phase of their treatment.

He is a long term survivor of Stage IV melanoma, having begun treatment for metastatic disease in November 1998. Following his treatment and recovery he began working at NCCS as a volunteer and subsequently moved into a position on the NCCS staff.

Among his patient advocate activities over the last several years are the following:

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Stakeholders Group, Appointed Nov. 2007
Member of Stakeholders Group for EGAPP initiative to conduct systematic reviews of evidence for the use of emerging genomic tests in medical practice and disease prevention.

AACR Scientist↔Survivor Program: 2003-2007
SSP advocate mentor, 2006, 2007
SSP Educational Workshop participant, 2005
SSP advocate participant, 2003, 2004

FDA Patient Consultant for melanoma, 2004 to present
FDA patient consultants are trained by the FDA and represent a patient perspective in the drug review process in settings that include end of Phase 2 meetings, advisory committee meetings and other settings as needed.

Accelerating Anticancer Agent Development and Validation Workshop, 2006, 2007, 2008 Bethesda, MD
Consumer faculty representative for the AAAD 2006, 2007 and 2008 workshops

Maryland State Council on Cancer Control, 2004 to present
Member